Cardium Therapeutics announced that its Chairman and CEO, Christopher J. Reinhard, will be one of the presenters at the Marcum MicroCap Conference on June 20, 2012, at 11:00 a.m. Eastern Time. A live audio webcast and replay of the presentation … Continue reading →

Earlier this morning, Cardium Therapeutics announced that it has signed an agreement with Advanced Biosciences Research, an affiliate of bioRASI, for the planned commercialization of Cardium’s professional-use Excellagen® topical wound care management product in Russia and the nine additional member … Continue reading →

MissionIR will be assisting Cardium Therapeutics in the implementation of a strategic digital and social media investor relations campaign. Through a network of investor-oriented sites and a full suite of investor awareness services, MissionIR develops and executes investor awareness plans … Continue reading →

Cardium Therapeutics is a health sciences and regenerative medicine company focused on acquiring and strategically developing new and innovative products and businesses to address significant unmet medical needs. Comprised of large-market opportunities with definable pathways to commercialization, partnering, and other … Continue reading →

Cardium Therapeutics, a San Diego based health sciences and regenerative medicine company, and its subsidiary, Tissue Repair Company, have contracted the Burlington, Massachusetts, site of Albany Molecular Research (AMRI) to manufacture sterile pre-filled syringes, in support of the U.S. introduction … Continue reading →

AMRI announced today that its Burlington site was contracted by Cardium Therapeutics and its subsidiary, Tissue Repair Company (“Cardium”) to manufacture sterile pre-filled syringes in support of the U.S. introduction of Excellagen®, a professional-use, formulated collagen-based product for the management … Continue reading →

Cardium Therapeutics today announced that Christopher J. Reinhard, Chairman & CEO will present a corporate overview and participate in a Regenerative Medicine Panel being held at the Sachs 2012 Science, Partner, and Investment Forum: Gateway for the Global Life Sciences … Continue reading →

Cardium Therapeutics today announced a late-breaking poster presentation at the American Society of Gene & Cell Therapy (ASGCT) 15th Annual Meeting being held May 16-19, 2012 at the Pennsylvania Convention Center in Philadelphia, PA. (Photo: http://photos.prnewswire.com/prnh/20120516/LA07787) (Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO) The new … Continue reading →

Cardium Therapeutics today announced an agreement with UK-based Angel Biomedical Limited, a subsidiary of Angel Biotechnology Holdings plc (AIM: ABH), a global biopharmaceutical contract manufacturer, covering the manufacture of formulated collagen for Cardium’s Excellagen® product, which was recently cleared for … Continue reading →

Cardium Therapeutics today presented its financial results for the first quarter ended March 31, 2012, and other recent developments. (Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO) In addition to the announcement of first quarter 2012 financial results, Cardium reported its goals for 2012, which were … Continue reading →